Kiniksa Pharmaceuticals International, plc (KNSA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Kiniksa has made significant progress in the development of ARCALYST for recurrent pericarditis, highlighting its commitment to addressing this medical condition [3] - The company is currently enrolling and dosing patients in a Phase II/III study for KPL-387, indicating ongoing research and development efforts [3] Leadership Insights - Sanj Patel, CEO and Chairman of the Board, expressed excitement about the company's advancements and future opportunities, reflecting a positive outlook on Kiniksa's trajectory [3]